Durability of seroconversion after long-term Lamivudine therapy in HBeAg positive chronic hepatitis B patients

被引：0
|
作者：
Ma, Xiuyun [1 ]
机构：
[1] Beijing Ditan Hosp, Outpatient Dept, Beijing, Peoples R China
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A110 / A110
页数：1
相关论文
共 50 条
  • [1] Durability of HBeAg seroconversion in chronic hepatitis B patients after lamivudine A-interferon or lamivudine A- interferon combination therapy
    Van Nunen, AB
    Hansen, B
    Suh, D
    Loehr, H
    Fontaine, H
    Chemello, L
    Song, B
    Heathcote, J
    Janssen, H
    de Man, RA
    Schalm, SW
    JOURNAL OF HEPATOLOGY, 2001, 34 : 155 - 155
  • [2] Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B
    Sokal, EM
    Kelly, DA
    Mizerski, J
    Badia, IB
    Areias, JA
    Schwarz, KB
    Vegnente, A
    Little, NR
    Gardener, SD
    Jonas, MM
    HEPATOLOGY, 2006, 43 (02) : 225 - 232
  • [3] Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: Response and relapse rates, and factors related to durability of HBeAg seroconversion
    Yoon, SK
    Jang, JW
    Kim, CW
    Bae, SH
    Choi, JY
    Choi, SW
    Lee, YS
    Lee, CD
    Chung, KW
    Sun, HS
    Kim, BS
    INTERVIROLOGY, 2005, 48 (06) : 341 - 349
  • [4] Long-term effect of lamivudine treatment in patients with chronic hepatitis B: How long should we continue lamivudine therapy after HBeAg loss or seroconversion?
    Hong, SP
    Han, KH
    Ahn, SH
    Paik, YH
    Lee, KS
    Chon, CY
    Moon, YM
    JOURNAL OF HEPATOLOGY, 2001, 34 : 154 - 154
  • [5] Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
    Hsu, YS
    Chien, RN
    Yeh, CT
    Sheen, IS
    Chiou, HY
    Chu, CM
    Liaw, YF
    HEPATOLOGY, 2002, 35 (06) : 1522 - 1527
  • [6] The influence of HBV genotype on the efficacy of long-term lamivudine therapy in patients with HBeAg positive chronic hepatitis B
    Zhu, Mei
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A110 - A110
  • [7] Efficacy of long-term lamivudine therapy in HBeAg negative chronic hepatitis B
    Dimou, E
    Papatheodoridis, GC
    Laras, A
    Rapti, I
    Dourakis, S
    Hadziyannis, SJ
    HEPATOLOGY, 1999, 30 (04) : 646A - 646A
  • [8] Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation
    Lee, CM
    Ong, GY
    Lu, SN
    Wang, JH
    Liao, CA
    Tung, HD
    Chen, TM
    Changchien, CS
    JOURNAL OF HEPATOLOGY, 2002, 37 (05) : 669 - 674
  • [9] Three-year durability of HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB).
    Willems, B
    Cianciara, J
    Karayalcin, S
    Kowdley, KV
    Plisek, S
    Woessner, M
    McMullen, S
    Gardner, S
    Schiff, E
    HEPATOLOGY, 2001, 34 (04) : 315A - 315A
  • [10] LONG-TERM OUTCOME OF LAMIVUDINE RESPONDER HBeAg NEGATIVE CHRONIC HEPATITIS B PATIENTS
    Ceylan, Bahadir
    Fincanci, Muzaffer
    Muderrisoglu, Cuneyt
    Soysal, Ferda
    Eren, Gulhan
    NOBEL MEDICUS, 2011, 7 (03): : 60 - 65
12345